What is he best known for?
The fields of study he is best known for:
- Bacteria
- Antibiotics
- Gene
His primary areas of study are Microbiology, Escherichia coli, Genetics, Antibiotic resistance and Plasmid.
Michael R. Mulvey studies Microbiology, namely Multiple drug resistance.
The Escherichia coli study combines topics in areas such as Molecular epidemiology and Drug resistance.
The various areas that Michael R. Mulvey examines in his Antibiotic resistance study include Biotechnology, Genome and Phylogenetic tree.
In his study, Complete sequence, Cloning, Molecular cloning and Complementation is inextricably linked to Transposable element, which falls within the broad field of Plasmid.
His studies in Virology integrate themes in fields like Methicillin-resistant Staphylococcus aureus and Staphylococcus aureus.
His most cited work include:
- The Comprehensive Antibiotic Resistance Database (930 citations)
- Multiplex PCR for the detection of tetracycline resistant genes. (529 citations)
- Complete Nucleotide Sequence of a 43-Kilobase Genomic Island Associated with the Multidrug Resistance Region of Salmonella enterica Serovar Typhimurium DT104 and Its Identification in Phage Type DT120 and Serovar Agona (361 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Microbiology, Antibiotic resistance, Escherichia coli, Plasmid and Multiple drug resistance.
A large part of his Microbiology studies is devoted to Drug resistance.
As a part of the same scientific family, Michael R. Mulvey mostly works in the field of Antibiotic resistance, focusing on Antimicrobial and, on occasion, Penicillin.
His study in Escherichia coli is interdisciplinary in nature, drawing from both Molecular epidemiology and Cephalosporin.
His studies deal with areas such as Replicon, Antibacterial agent, Intensive care and Genotype as well as Multiple drug resistance.
Michael R. Mulvey works mostly in the field of Salmonella enterica, limiting it down to concerns involving Serotype and, occasionally, Streptococcus pneumoniae.
He most often published in these fields:
- Microbiology (86.86%)
- Antibiotic resistance (25.55%)
- Escherichia coli (21.53%)
What were the highlights of his more recent work (between 2018-2021)?
- Microbiology (86.86%)
- Antibiotic resistance (25.55%)
- Escherichia coli (21.53%)
In recent papers he was focusing on the following fields of study:
Michael R. Mulvey mainly focuses on Microbiology, Antibiotic resistance, Escherichia coli, Colistin and Drug resistance.
His Microbiology research integrates issues from Plasmid and Klebsiella pneumoniae.
Michael R. Mulvey works mostly in the field of Plasmid, limiting it down to topics relating to Multiple drug resistance and, in certain cases, Horizontal gene transfer, Feces and Ceftiofur, as a part of the same area of interest.
His work deals with themes such as Ciprofloxacin, Antimicrobial, Salmonella and Carbapenem, which intersect with Antibiotic resistance.
His Escherichia coli research focuses on Whole genome sequencing and how it connects with Mobile genetic elements, Beef cattle, Gene family and Cephalosporin Resistance.
Michael R. Mulvey interconnects Tigecycline, Internal medicine, Ceftolozane and Tazobactam in the investigation of issues within Colistin.
Between 2018 and 2021, his most popular works were:
- Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study. (13 citations)
- 42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. (13 citations)
- 42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. (13 citations)
In his most recent research, the most cited papers focused on:
- Bacteria
- Antibiotics
- Gene
His primary scientific interests are in Microbiology, Colistin, Tigecycline, Tazobactam and Ceftolozane.
Microbiology is closely attributed to Klebsiella pneumoniae in his research.
Michael R. Mulvey has included themes like Plasmid, Amikacin, Hospital admission, Sequence and Rectal swab in his Klebsiella pneumoniae study.
His research investigates the connection with Colistin and areas like Broth microdilution which intersect with concerns in Meropenem and Multilocus sequence typing.
His Tigecycline research focuses on Ertapenem and how it relates to Telavancin and Internal medicine.
His Tazobactam study integrates concerns from other disciplines, such as Methicillin-resistant Staphylococcus aureus and Ceftobiprole.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
